Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OPN 2853

Drug Profile

OPN 2853

Alternative Names: OPN-2853; PLX-2853

Latest Information Update: 02 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Plexxikon
  • Developer Daiichi Sankyo Company; Opna Bio; University of Birmingham
  • Class Antineoplastics; Small molecules
  • Mechanism of Action BRD4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Myelofibrosis
  • Discontinued Acute myeloid leukaemia; Graft-versus-host disease; Gynaecological cancer; Haematological malignancies; Myelodysplastic syndromes; Ovarian cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 02 Feb 2024 OPN 2853 is available for licensing as of 24 Jan 2024 (https://www.opnabio.com/pipeline/)
  • 14 Apr 2023 Efficacy and adverse event data from phase Ib/IIa trial in Ovarian cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
  • 25 Jan 2023 Discontinued - Phase-I for Acute myeloid leukaemia (Second-line therapy or greater) in USA (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top